Tenofovir/Emtricitabine/Efavirenz Plus Rosuvastatin Decrease Serum Levels of Inflammatory Markers More Than Antiretroviral Drugs Alone in Antiretroviral Therapy-Naive HIV-Infected Patients

REFERENCES

• Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists’ Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278.
   PubMed Web of Science ®Google Scholar
• Lamon-Fava S. Statins and lipid metabolism: An update. Curr Opin Lipidol. 2013;24: 221–226.
   PubMed Web of Science ®Google Scholar
• Peters SA, Palmer MK, Grobbee DE, et al. C-reactive protein lowering with rosuvastatin in the METEOR study. J Intern Med. 2010;268:155–161.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet. 2009;373:1175–1182.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Liao JK. Pleiotropic effects of statins: Basic research and clinical perspectives. Circ J. 2010;74: 818–826.
   PubMed Web of Science ®Google Scholar
• Ota H, Eto M, Kano MR, et al. Induction of endothelial nitric oxide synthase, SIRT1, and catalase by statins inhibits endothelial senescence through the Akt pathway. Arterioscler Thromb Vasc Biol. 2010;30:2205–2211.
   PubMed Web of Science ®Google Scholar
• Antoniades C, Bakogiannis C, Tousoulis D, et al. Preop-erative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity. Circulation. 2010;122:S66–S73.
   PubMed Web of Science ®Google Scholar
• Jougasaki M, Ichiki T, Takenoshita Y, et al. Statins sup-press interleukin-6-induced monocyte chemo-attarctant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascu-lar endothelial cells. Br J Pharmacol. 2010;159:1294–1303.
   PubMed Web of Science ®Google Scholar
• Merx MW, Liehn EA, Janssens U, et al. HMG-CoA reduc-tase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation. 2004;109:2560–2565.
   PubMed Web of Science ®Google Scholar
• Rosch JW, Boyd AR, Hinojosa E, et al. Statins protect against fulminant pneumococcal infection and cytolysin toxicity in a mouse model of sickle cell disease. J Clin Invest. 2010;120:627–635.
   PubMed Web of Science ®Google Scholar
• Amuro H, Ito T, Miyamoto R, et al. Statins, inhibitors of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, func-tion as inhibitors of cellular and molecular components involved in type 1 interferon production. Arthritis Rheum. 2010;62:2073–2085.
   PubMed Web of Science ®Google Scholar
• Risk assessment tool for estimation 10-year risk of devel-oping hard CHD (myocardial infarction and coronary death). http://hp2010.nhIbihin.net/atpiii/calculator.asp?usertype=prof
   Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Pro-gram (NCEP) on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421.
   PubMed Web of Science ®Google Scholar
• Kuller LH, Tracy R, Belloso W, et al. Inflammation and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5:e203.
   PubMed Web of Science ®Google Scholar
• Duprez DA, Neuhaus J, KuIler LH, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One. 2012;7:e44454.
   PubMed Web of Science ®Google Scholar
• Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr. 2009;51:268–273.
   PubMed Web of Science ®Google Scholar
• Tien PC, Choi Al, Zolopa AR, et al. Inflammation and mor-tality in HIV-infected adults: Analysis of the FRAM study cohort. J Acquir Immune Defic Syndr. 2010;55:316–322.
   PubMed Web of Science ®Google Scholar
• Mangili A, Polak JF, Quach LA, Gerrior J, Wanke CA. Markers of atherosclerosis and inflammation and mortality in patients with HIV infection. Atherosclerosis. 2011214: 468–473.
   Google Scholar
• McDonald B, Moyo S, Gabaitiri L, et al. Persistently ele-vated serum interleukin-6 predicts mortality among adults receiving combination antiretroviral therapy in Botswana: Results from a clinical trial. AIDS Res Hum Retroviruses. 2013;29:993–999.
   PubMed Web of Science ®Google Scholar
• Lau B, Sharrett AR, Kingsley LA, et al. C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med. 2006;166:64–70.
   PubMed Web of Science ®Google Scholar
• Feldman JG, Goldwasser P, Holman S, DeHovitzJ, Minkoff H. C-reactive protein is an independent predictor of mor-tality in women with HIV-1 infection. J Acquire Immune Defic Syndr. 2003;32:210–214.
   PubMed Web of Science ®Google Scholar
• Bu D, Griffin G, Lichtman AH. Mechanisms for the anti-inflammatory effects of statins. Curr Opin Lipidol. 2011;22:165–170.
   PubMed Web of Science ®Google Scholar
• Quist-Paulsen P. Statins and inflammation: An update. Curr Opin Cardiol. 2010;25:399–405.
   PubMed Web of Science ®Google Scholar
• Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92:152–160.
   PubMed Web of Science ®Google Scholar
• Schuster H, Barter PJ, Stender S, et al. Effects of switch-ing statins on achievement of lipid goals: Measuring Effec-tive Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J. 2004;147:705–712.
   PubMed Web of Science ®Google Scholar
• Crouse JR, Raichlen JS, Riley WA, et al. Effect of rosuv-astatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis. JAMA. 2007;297:1344–1353.
   PubMed Web of Science ®Google Scholar
• Tawakol A, Fayad ZA, Mogg R, et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: Results of a multi-center FDG-PET/CT feasi-bility study [published online ahead of print May 30,2013]. J Am Coll Cardiol.
   Google Scholar
• Liu B, Zhang JY, Cao HM, et al. Effect of rosuvastatin on ROCK activity, endothelial function, and inflammation in Asian patients with atherosclerosis. Intern Med. 2012;51:1177–1182.
   PubMed Web of Science ®Google Scholar
• Maziere JC, Landureau JC, Giral P, et al. Lovastatin inhib-its HIV-1 expression in H9 human T lymphocytes cul-tured in cholesterol-poor medium. Biomed Pharmacother. 1994;48:63–67.
   PubMed Web of Science ®Google Scholar
• Giguère JF, Tremblay MJ. Statin compounds reduce human immunodeficiency virus type 1 replication by pre-venting the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell sur-face ligand LFA-1. J Virol. 2004;78:12062–12065.
   PubMed Web of Science ®Google Scholar
• Moncunill G, Negredo E, Bosch L, et al. Evaluation of the anti-HIV activity of statins. AIDS. 2005;19:1697–1700.
   PubMed Web of Science ®Google Scholar
• Amet T, Nonaka M, Dewan MZ, et al. Statin-induced inhibi-tion of HIV-1 release from latently infected U1 cells reveals a critical role for protein prenylation in HIV-1 replication. Microbes Infect. 2008;10:471–480.
   PubMed Web of Science ®Google Scholar
• Negredo E, Clotet B, Puig J, et al. The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretro-viral therapy. AIDS. 2006;20:619–621.
   PubMed Web of Science ®Google Scholar
• Sklar PA, Masur H, Grubb JR, et al. Pravastatin does not have a consistent antiviral effect in chronically HIV-infected individuals on antiretroviral therapy. AIDS. 2005;19: 1109–1111.
   PubMed Web of Science ®Google Scholar
• Ganesan A, Crum-Cianflone N, Higgins J, et al. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: Results of a double-blind randomized placebo controlled clinical trial. J Infect Dis. 2011;203:756–764.
   PubMed Web of Science ®Google Scholar
• Aslangul E, Fellahi S, Assoumou LK, et al. High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors. AIDS. 201125: 1128–1131.
   Google Scholar
• Calza L, Trapani F, Bartoletti M, et al. Statin therapy decreases serum levels of high-sensitivity C-reactive pro-tein and tumor necrosis factor-a in HIV-infected patients treated with ritonavir-boosted protease inhibitors. HIV Clin Trials. 2012;13:153–161.
   PubMed Web of Science ®Google Scholar
• Fichtenbaum CJ, Evans SE, Aberg JA. High-sensitiv-ity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection. AIDS. 201125:2053.
   Google Scholar
• De Wit S, Delforge M, Necsoi CV, Clumeck N. Down regulation of CD38 activation markers by atorvastatin in HIV patients with undetectable viral load. AIDS. 2011;25: 1332–1333.
   PubMed Web of Science ®Google Scholar
• Moore RD, Bartlett JG, Gallant JE. Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients. PLoS One. 2011;6:e21843.
   PubMed Web of Science ®Google Scholar
• Rasmussen LD, Kronborg G, Larsen CS, Pedersen C, Ger-stoft J, Obel N. Statin therapy and mortality in HIV-infected individuals; a Danish nationwide population-based cohort study. PLoS One. 2013;8:e52828.
   PubMed Web of Science ®Google Scholar
• Higuita EA, Jaimes FA, Rugeles MT, Montoya CJ. In vivo effect of statins on the expression of the HIV co-receptors CCR5 and CXCR4 [published online ahead of print May 1, 2013]. AIDS Res Ther
   PubMed Web of Science ®Google Scholar